Maternal fetal complications of sickle cell anemia in pregnant women: literature review
Keywords:
ANEMIA DE CÉLULAS FALCIFORMES; COMPLICACIONES; EMBARAZO, FETAL., SICKLE CELL ANEMIA; COMPLICATIONS; PREGNANCY; FETAL.Abstract
Introduction: the drepanocitosis is in the entire world one of the illnesses monogenic hereditary more communes, it is a dysfunction genetic recessive autonomic that characterized by a punctual mutation of the hemoglobin.
Objective: to evaluate the maternal and fetal complications of sickle cell anemia in pregnant women.
Methods: it was carried out a bibliographical revision in the period of January from the 2024 to January of the 2025, articles of available complete text were included, of the last 5 years in English and Spanish language. You proceeded to the search of the different scientific articles in the databases Pubmed, Google Scholar, Web of Science (WoS), Scopus, Europe PMC and Scielo.
Development: among the complications of the illness, they highlight in the mother the sharp thoracic syndrome, the preeclampsia, the crises vasooclusivas and a high risk of mortality; while in the fetus the restriction of the intra-uterine growth, the prematuridad and the intra-uterine death prevail. The integral handling includes specialized prenatal controls, prevention of infections, appropriate suplementación and therapies like transfusions of red globules, it has demonstrated to reduce these risks.
Conclusion: the anemia of falciform cells during the pregnancy represents a significant clinical challenge, associating with a fetal maternal substantial increment of complications. Advance as the therapy génica they offer promising perspectives when approaching the genetic cause of the illness. The combination of rigorous medical pursuit, education for the health and therapeutic innovation constitutes the angular stone for the treatment of this hemoglobinopatía.
Downloads
References
1. Hazin-Costa MF, da Silva Aráujo A, Guerra GL, da Matta MC, Torres LC, Souza AI. Chemokines in pregnant women with sickle cell disease. Cytokine. [Internet]. 2019 Jan [citado: 01/03/2024]; 113: 195–9. Disponible en: https://doi.org/10.1016/j.cyto.2018.07.002
2. Piel FB, Steinberg MH, Rees DC. Sickle Cell Disease. Longo DL, editor. New England Journal of Medicine [Internet]. 2017 Apr [citado: 01/03/2024]; 376(16): 1561–73. Disponible en: http://www.nejm.org/doi/10.1056/NEJMra1510865
3. Baralis Aragón P, Bonilla Álvarez G, Ye Ng LYM. Drepanocitosis en embarazo. Rev. Medica Sinergia. [Internet]. 2020 Dec [citado: 01/03/2024]; 5(12): e621. Disponible en: https://revistamedicasinergia.com/index.php/rms/article/view/621
4. Saraf SL, Molokie RE, Nouraie M, Sable CA, Luchtman-Jones L, Ensing GJ, et al. Differences in the clinical and genotypic presentation of sickle cell disease around the world. Vol. 15, Paediatric Respiratory Reviews. [Internet]. 2015 [citado: 01/03/2024]; 15(1): 4–12. Disponible en: https://doi.org/10.1016/j.prrv.2013.11.003
5. Aghamolaei T, Pormehr-Yabandeh A, Hosseini Z, Roozbeh N, Arian M, Ghanbarnezhad A. Pregnancy in the Sickle Cell Disease and Fetomaternal Outcomes in Different Sickle cell Genotypes: A Systematic Review and Meta-Analysis. Ethiop J Health Sci. [Internet]. 2022 Jul [citado: 01/03/2024]; 32(4): 849–64. Disponible en: https://doi.org/10.4314/ejhs.v32i4.23
6. Jain D, Atmapoojya P, Colah R, Lodha P. Sickle cell disease and pregnancy. Mediterranean Journal of Hematology and Infectious Diseases. Universita Cattolica del Sacro Cuore [Internet]. 2019 [citado: 01/03/2024]; 11(1): e2019040. Disponible en: https://doi.org/10.4084/mjhid.2019.040
7. Martínez-Sánchez LM, Villegas-Alzate JD, Herrera-Almanza L, Correa-Saavedra MA, Gálvez-Cárdenas KM, Hernández-Martínez A, et al. Characterization of patients with sickle cell anemia in Medellin, Colombia. Medicina Interna de Mexico. [Internet]. 2022 Sep [citado: 01/03/2024]; 38(5): 1012–8. Disponible en: https://www.medigraphic.com/pdfs/medintmex/mim-2022/mim225e.pdf
8. Quiñonez Lugo MC. Estilos de vida en personas con anemia drepanocítica en el Cantón San Lorenzo [Tesis] Pontificia Universidad Católica del Ecuador[Internet]; 2017[citado: 01/03/2024]. Disponible en: https://repositorio.puce.edu.ec/handle/123456789/37064
9. Sousa VT de, Ballas SK, Leite JM, Olivato MCA, Cancado RD. Maternal and perinatal outcomes in pregnant women with sickle cell disease: an update. Hematol Transfus Cell Ther [Internet]. 2022 [citado: 01/03/2024]; 44(3): 369-73. Disponible en: http://dx.doi.org/10.1016/j.htct.2020.12.009
10. Adesina OO, Brunson A, Fisch SC, Yu B, Mahajan A, Willen SM, Keegan THM, Wun T. Pregnancy outcomes in women with sickle cell disease in California. Am J Hematol. [Internet]. 2023 Mar [citado: 01/03/2024]; 98(3): 440-448. Disponible en: http://dx.doi.org/10.1002/ajh.26818
11. Lewis G, Thame M, Howitt C, Hambleton I, Serjeant GR. Pregnancy outcome in homozygous sickle cell disease: observations from the Jamaican Birth Cohort. BJOG [Internet]. 2021 [citado: 01/03/2024]; 128(10): 1703-10. Disponible en: http://dx.doi.org/10.1111/1471-0528.16696
12. Habibi A, Cannas G, Bartolucci P, Voskaridou E, Joseph L, Bernit E, et al. Outcomes of Pregnancy in Sickle Cell Disease Patients: Results from the Prospective ESCORT-HU Cohort Study. Biomedicines [Internet]. 2023 [citado: 01/03/2024]; 11: 597. Disponible en: https://doi.org/10.3390/biomedicines11020597
13. Prado-Molina DG, SernaTrejos JS, Quijano-Navarrete M. Primera terapia por edición génica en anemia de células falciformes: dilemas bioéticos. Rev Hisp Cienc Salud. [Internet]. 2024; [citado: 01/03/2024]; 10(1): 53-54. Disponible en: https://doi.org/10.56239/rhcs.2024.101.717
14. Olivo-Yepez A, Linares-Márquez P, Delgado-Enciso I, Morales-Romero Z. La terapia génica en México y España, una aproximación bioética desde la investigación científica. Rev. Bioética y Derecho [Internet]. 2021 [citado: 01/03/2024]; (53): 117-138. Disponible en: http://scielo.isciii.es/scielo.php?script=sci_arttext&pid=S1886-58872021000300007&lng=es
15. Lucero Flores KG, Reyes Rosero EA. Terapias génicas para tratar a pacientes con anemia de células falciformes. Revisión de literatura. Cienc. educ. (Holguin) [Internet]. 5 de abril de 2025 [citado: 15/04/2024]; 291-301. Disponible en: https://cienciayeducacion.com/index.php/journal/article/view/zenodo.15178002
16. Duque EL, Saavedra VME, Vergara YD, et al. Anemia de células falciformes en medicina de urgencias: una revisión basada en la evidencia. Med Int Mex. [Internet]. 2024 [citado: 01/03/2024]; 40(09): 581-590. Disponible en: https://www.medigraphic.com/pdfs/medintmex/mim-2024/mim249d.pdf
17. Shah N, Bhor M, Xie L, Paulose J, et al. Sickle cell disease complications: Prevalence and resource utilization. PLoS One [Internet]. 2019 [citado: 01/03/2024]; 14(7): e0214355. Disponible en: https://doi.org/10.1371/journal.pone.0214355
18. Hequet O, Fort R, Driss F. Red blood cell exchange in an emergency in sickle cell disease. Transfus Apher Sci [Internet]. 2020 [citado: 01/03/2024]; 59(6): 102996. Disponible en: https://doi.org/10.1016/j.transci.2020.102996
19. Ramsay Z, Bartlett R, Ali A, Grant J, et al. Sickle Cell Disease and Pain: Is it all Vaso-occlusive Crises? Clin J Pain [Internet]. 2021 [citado: 01/03/2024]; 37(8): 583-90. Disponible en: https://doi.org/10.1097/AJP.0000000000000949
20. Gaitán-Lee H, Chacón-Cas-tillo CL, Stangl-Correa WP, Stangl-Herera WP, Alzate-Chacón RI, Gómez-Menéndez JM, et al. Protocolo multidisciplinario para el manejo de pacientes con anemia de células falciformes llevados a artro-plastia total de cadera. Experiencia en un hospital de Cali, Colombia. Rev Col Or Tra. [Internet]. 2024 [citado: 01/03/2024]; 38(2): e97. Disponible en: https://doi.org/10.58814/01208845.97
21. Piel FB, Rees DC, DeBaun MR, Nnodu O, Ranque B, Thompson AA, et al. Defining global strategies to improve outcomes in sickle cell disease: a Lancet Haematology Commission. Lancet Haematol. [Internet]. 2023 [citado: 01/03/2024]; 10(8): e633-e686. Disponible en: https://pubmed.ncbi.nlm.nih.gov/37451304/
22. Morón Serrano SJ, Giraldo Cuartas CE, Ariza Parra EJ, Gaviria Jaramillo LM, Hernández Rodríguez JC, Cárdenas Ramos RM, et al. Indicaciones y complicaciones del soporte transfusional en pacientes con enfermedad de células falciformes. Acta Médica Colombiana [Internet]. 2025 [citado: 08/02/2025]; 50(2). Disponible en: https://doi.org/10.36104/amc.2025.3785
23. Rollins MR, Chou ST. Adverse events of red blood cell transfusions in patients with sickle cell disease. Transfus Apher Sci. [Internet]. 2022 [citado: 08/02/2025]; 61(5): 103557. Disponible en: https://pubmed.ncbi.nlm.nih.gov/36064527/
24. Ackfeld T, Schmutz T, Guechi Y, Le Terrier C. Blood Transfusion Reactions—A Comprehensive Review of the Literature including a Swiss Perspective. J Clin Med. [Internet]. 2022 [citado: 08/02/2025]; 11(10): 2859. Disponible en: https://pubmed.ncbi.nlm.nih.gov/35628985/
Additional Files
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Santiago Xavier Peñarreta-Quezada, Karla Magaly Sánchez-Sánchez, Paulette Baymar González-Rojas, Marcela Estefania Chalacán-Castro
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Authors who have publications with this journal agree to the following terms: Authors will retain their copyrights and grant the journal the right of first publication of their work, which will be publication of their work, which will be simultaneously subject to the Creative Commons Attribution License (CC-BY-NC 4.0) that allows third parties to share the work as long as its author and first publication in this journal are indicated.
Authors may adopt other non-exclusive license agreements for distribution of the published version of the work (e.g.: deposit it in an institutional telematic archive or publish it in a volume). Likewise, and according to the recommendations of the Medical Sciences Editorial (ECIMED), authors must declare in each article their contribution according to the CRediT taxonomy (contributor roles). This taxonomy includes 14 roles, which can be used to represent the tasks typically performed by contributors in scientific academic production. It should be consulted in monograph) whenever initial publication in this journal is indicated. Authors are allowed and encouraged to disseminate their work through the Internet (e.g., in institutional telematic archives or on their web page) before and during the submission process, which may produce interesting exchanges and increase citations of the published work. (See The effect of open access). https://casrai.org/credit/
